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The anticancer drug cisplatin (CP) is loaded into SBA-15 mesoporous silica (SBA-15|CP) and its release from
the nanomaterial is studied. The CP-loaded SBA-15 is tested against four tumor cell lines: mouse malignant
melanoma B16F10, human adenocarcinoma HeLa, colon HT-29 and prostate PC3. Most importantly, the
superiority of this novel material in comparison to CP arises from the fact that the CP-grafted
nanomaterial SBA-15 (/SBA-15|CP) is enhancing cessation of proliferation along with induction of
senescence in B16F10 in approximately 3.5 times lower concentration. The control material loaded with
therapeutically inactive K2[PtCl4] (/SBA-15|TC) showed no antitumor activity. To a large extent, SBA-
15|CP-induced senescence might present a safe approach in tumor treatment. Such cells can be cleared
by immune cells resulting in eﬃcient tumor regression. So far only apoptotic agents are being exploited
in clinics, thus an understanding of the chemotherapeutic-induced senescence will allow oncologists to
explore this essential tumor suppressor mechanism.1 Introduction
Conventional therapeutics, such as cisplatin, beside their bene-
cial eﬀects in the ght against cancer, confront quite a few
challenges.1 The main goals of chemotherapeutics are to hinder
the tumor expansion, reduce growth of tumor cells and increase
the patient's survival period. Cisplatin (CP), a cell-type specic
drug, alone or in combined therapywith other drugs, is a rst-line
agent for several cancers, e.g. testicular, ovarian, lung, head and
neck tumors. Nevertheless, its antitumor eﬃciency is limited due
to dose-dependent toxicities (e.g. nephro- and neurotoxicities)
and intrinsic or acquired cellular resistance.2,3 Beside these,
several additional concerns are important to resolve in order to
improve its therapeutic eﬀectiveness.4 Explicitly, one of the main
obstacles comes from the fast deactivation of CP.5 Thus, CP non-
specic binds to proteins present in the blood stream.
Upon discovery of CP anticancer drug development is
pointed in several directions. One development concerns
constitutional variations around platinum center, yielded in
second (carboplatin, nedaplatin) and third generations (oxali-
platin, satraplatin) of platinum-based drugs,6,7 as well as
exploration of potential of non-platinum metal-based drugseibniz Institute of Plant Biochemistry,
. E-mail: goran.kaluderovic@ipb-halle.de
iversity Halle-Wittenberg, Kurt-Mothes-
Reconstructive Plastic Surgery, University
pzig, Germany
hemistry, Technology and Metallurgy,
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hemistry 2016(e.g. ruthenium(II/III), gold(III), tin(IV), titanium(IV), etc.).8–13
Another is directed to development of chemical conjugation of
CP using polymers.14,15 However, these strategies in general face
similar problems as CP. Moreover in some cases even poorer
water solubility is achieved for some potential drugs, which
resulted in less therapeutic potentials. The polymer approach
concerning coordination of polymer carboxylato groups to
platinum(II) center showed to be unsuccessful for the desired
controlled drug release at the target tumor sites.6
Alternative approach employing delivery systems through
physical adsorption and trapping has been also explored.16 Even
some attempts in the recent time were made, targeted delivery
of CP to tumor cells without damaging healthy tissues and
organs is very diﬃcult, if not realizable with current technolo-
gies.17 The rationale of loading of highly active anticancer
compounds into particles, as mentioned above, lies in the
following: prevention of hydrolysis and accumulation in the
healthy tissues/organs, tailorable drug release, as well as local
application in tumor tissues in high doses.18,19 In last few years
mesoporous silica materials are explored as carrier particles for
various type of drugs (e.g. anti-inammatory, anticancer
drugs).20–22 Depending on the size of nanoparticles used they
may be physiologically safe and exhibit no toxicity.23,24 This
principle has already been explored through a number of works,
therefore such nontoxic materials are suitable as drug carriers.25
Moreover, these materials reach malignant tissue quickly, thus
lower concentration of medication eﬃciently aﬀect tumor with
less side eﬀects. Typical nontoxic materials are structured
mesoporous silica, such as MCM-41 (Mobil Composition of
Matter 41), SBA-15 (Santa Barbara Amorphous 15) or TUD-1RSC Adv., 2016, 6, 111031–111040 | 111031
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View Article Online(Del University of Technology 1).26 There are several reports in
the literature on the mesoporous silica loaded with CP.
However, mainly employing diﬀerent mesoporous silica nano-
particle types or sizes, functionalization as well as codelivery
with other drugs and or proteins.27–40 Beside investigations in
drug delivery suchmaterials are also applied as inert carriers for
various other molecules (e.g. catalysts).41,42
Pioneering investigations related to mesoporous silica
loaded with metal complexes as potential anticancer delivery
systems began in 2009.43 SBA-15 and MCM-41 loaded with
titanium(IV) and tin(IV) compounds have been investigated.43–47
SBA-15 was found to be superior to MCM-41 as carrier system,
as well as organotin(IV) over titanium(IV) compounds. Thus,
modied SBA-15 carrying organotin(IV) compound Ph3-
Sn(CH2)6OH was more than 150 times more active than SBA-15
loaded with the most eﬀective titanium(IV) complex. Strong
therapeutic potential of organotin(IV) loaded mesoporous silica
lie in development of a nonproliferative melanocyte-like
phenotype of surviving cells. Thus, this nonaggressive
suppression of tumor growth with nontoxic doses of the drug is
highly eﬃcient against melanoma cells. Contrarily to the
conventional approach in oncotherapy (induction of apoptosis),
transformation of malignant phenotype into senescence and
Schwann-like cells presents also non aggressive mode of drug
action, all of them do not cause proliferative compensation.
The focus of this work is on the CP loaded SBA-15 (/SBA-
15|CP) as a simple delivery system with clinically used drug.
Preparation, characterization and drug release studies are per-
formed. The SBA-15|CP is tested against four tumor cell lines.
On the most active B16F10 cell cycle perturbation, apoptosis,
autophagy, ROS, proliferation potential and senescence induc-
tion upon treatment have been evaluated.
2 Experimental section
2.1 Materials and methods
K2[PtCl4] (Merck), cisplatin (CP), pluronic 123 (P123) and TEOS
(Sigma) were purchased and used as received from distributor.
2.2 Characterization of the MSNs
SEM and TEM imaging were performed on JEM-1010 (JEOL).
EDX experiments were conducted on electron microscope JSM-
6701F and JSM-7500F (JEOL) as well as XL 30 ESEM-FEG (Phi-
lips). Sorptomatic 1900 Turbo Analysator (Carlo Erba Instru-
ments) and NOVA 1000 (Quantachrome) were employed for
nitrogen adsorption–desorptionmeasurements. IR spectra were
recorded on IR-Spectrometer Tensor 27 Platinum (Bruker) in
the range 4000–200 cm1. X-ray measurements (SAXS) were
performed on a D8 ADVANCE (Bruker) X-ray diﬀraction system.
ICP MS analysis was performed on Thermo Scientic iCAP Qc
ICP-MS (Thermo Scientic, Bremen, Germany) spectrometer
with operational soware Qtegra.
2.3 Preparation of SBA-15 (ref. 48)
For the synthesis following materials were used: P123 (24.2
g), water (180 mL), HCl (2 M, 720 g) and TEOS (51 g). Obtained111032 | RSC Adv., 2016, 6, 111031–111040material was heated (1 K min1) to 500 C and calcied for
24 h. Yield: 15.6 g; BET surface: 810 m2 g1; pore volume:
0.83 cm3 g1; pore diameter: 4.88 nm; wall thickness:
4.39 nm; 29Si MAS NMR (80 MHz, d): 108.9 (s), 101.4 (s),
91.5 (s); IR: n ¼ 1061 (br, vs; Si–O–Si), 806 (w; Si–O–Si), 443
cm1 (vs; Si–O–Si); XRD (2q in , Miller indices): 0.9512 (100),
1.6647 (111), 1.8956 (200); lattice parameter (nm): 9.3; crystal
size (nm): 75.50.2.4 Preparation of SBA-15|TC and SBA-15|CP
Graing of SBA-15 was performed similarly to the procedure
described in the literature.44,49 SBA-15 (200 mg) was activated by
drying under vacuum at 150 C for 16 h. K2[PtCl4] (83 mg) and
cisplatin (60 mg) respectively were suspended in toluene
(20 mL). Obtained suspension was added to the activated SBA-
15 and the mixture was stirred at 80 C for 48 h. Aerwards
reaction mixture was ltered and isolated material was washed
successively with toluene (2  10 mL) and n-pentane (3  10
mL). Obtained MSNs were dried under vacuum at room
temperature.
SBA-15|TC. Yield: 279 mg; BET surface: 522 m2 g1; pore
volume: 0.55 cm3 g1; pore diameter: 4.62 nm; wall thickness:
4.64 nm; 29Si MAS NMR (80 MHz, d): 110.0 (s), 101.6 (s),
91.6 (s); IR: n ¼ 1061 (br vs; Si–O–Si), 806 (w; Si–O–Si), 443 (vs;
Si–O–Si), 325 cm1 (s, Pt–Cl); XRD (2q in , Miller indices):
0.9512 (100), 1.6647 (111), 1.8956 (200); lattice parameter (nm):
9.3; crystal size (nm): 77.54.
SBA-15|CP. Yield: 253 mg; BET surface: 561 m2 g1; pore
volume: 0.59 cm3 g1; pore diameter: 4.41 nm; wall thickness:
4.51 nm; 29Si MAS NMR (80 MHz, d): 108.2 (s), 101.1 (s),
91.0 (s); IR: n ¼ 1061 (br, vs; Si–O–Si), 806 (w; Si–O–Si), 443 (vs;
Si–O–Si), 325 cm1 (s, Pt–Cl); XRD (2q in , Miller indices):
1.0142 (100), 1.6962 (111), 1.9585 (200); lattice parameter (nm):
8.9; crystal size (nm): 75.26.2.5 Platinum release study
Aer desorption of platinum(II) compounds from the SBA-15|
TC and SBA-15|CP in puried water (sampling aer time 0.08,
0.5, 1, 3, 6, 12, 24 and 48 h), solid samples were analysed with
EDX (no further sample preparation) while platinum content
in liquid samples was investigated with ICP-MS. Explicitly,
liquid samples were diluted with puried water (1 : 100, v/v).
The Thermo Scientic iCAP Qc ICP-MS instrument was opti-
mized for optimum performance in He KED (kinetic energy
discrimination) mode using the supplied autotune protocols.
The ICP-MS instrument was tuned using a solution TUNE B
iCAP Q (1 mg L1 of each: Ba, Bi, Ce, Co, In, Li, U) provided by
the manufacturer Thermo Scientic, Germany. External Stan-
dards for the instrument calibration were prepared on the
basis of a platinum plasma standard solution (Specpure®, Pt
1000 mg mL1 certied reference solution ICP Standard
purchased from Alfa Aesar GmbH & Co KG, Germany). For
water extracts, the limit of quantitation (LOQ) for platinum
was determined to be 46 ng L1. The measurement was per-
formed on isotope 194Pt.This journal is © The Royal Society of Chemistry 2016
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View Article Online2.6 In vitro studies
CV, MTT, DAPI, CFSE (Sigma-Aldrich), RPMI-1640, phosphate-
buﬀered saline (PBS), penicillin/streptomycin, 10 Dulbeccos
PBS without Ca2+ and Mg2+, trypsin–EDTA 0.05%/0.02% (PAA
Laboratories GmbH), proteinase K 20 mg mL1 in PBS, RNAse A
(Roche Diagnostics GmbH), DHR (VWR), annexin V/PI (BD
Pharmagen), PI (BD Pharmagen), SA-b-Gal assay (Cell Signaling
Technology) were used. B16F10 mouse skin melanoma and
HT-29 colon adenocarcinoma cells were kindly obtained from
Prof. B. Seliger (Martin Luther University Halle-Wittenberg,
Germany), while HeLa human cervix adenocarcinoma cells
from Ontochem (Halle, Germany). PC3 human refractory pros-
tate cancer cells was purchased from the German Collection of
Microorganisms and Cell Cultures (DSMZ, Germany). Tumor cell
lines B16F10, HeLa, HT-29 and PC3 were routinely maintained
in RPMI-1640 medium supplemented with 10% FCS and 1%
antibiotics (culture medium) at 37 C in a humidied atmo-
sphere with 5% CO2. Stock solutions of platinum(II) complexes
(20mM) andMSNs (20mgmL1) were freshly prepared in DMSO
or in PBS, respectively, and diluted to various working concen-
trations with medium. Microphotographs were obtained using
a uorescence microscope (Carl Zeiss). Flow cytometry was per-
formed on BD FACS Aria III and analyzed using BD FACSDiva
soware (BD Biosciences, Heidelberg, Germany).
2.7 CV and MTT assays
The viability of the cells was measured by CV and MTT assays as
described previously.50 Absorbance was measured using a 96-
well plate reader (Tecan Spectra, Crailsheim, Germany). IC50
[mM] and MC50 [mg mL
1] values, dened as the concentration
of the compounds at which 50% of cell inhibition occur were
calculated using four-parameter logistic function and presented
as mean from three independent experiments.
2.8 Cell cycle analysis
In the 6 well plate 1  105 B16F10 cells per well were incubated
with IC50, 2  IC50 or MC50, 2  MC50 doses of CP and SBA-
15|CP for 24 and 48 h and cell cycle analysis was performed
using DAPI stain.
2.9 Apoptosis detection
In the 6 well plate 1  105 B16F10 cells per well were incubated
with IC50, 2  IC50 or MC50, 2  MC50 doses of CP and
SBA-15|CP for 24 and 48 h. Aerwards, annexin V/PI protocol
was applied as described in the literature.51
2.10 Morphological analysis (AO staining)
A staining of the B16F10 cells with AO (Sigma-Aldrich),
according to standard procedures,52 was used for this
purpose. B16F10 cells were seeded overnight on 4 chamber slide
(1  104 cells per chamber) in 500 mL of complete medium. The
next day, cells were treated with 2  IC50 and 2 MC50 doses of
CP and SBA-15|CP, respectively for 24 h. Aerwards, cells on the
slides were stained with AO (3 mg mL1 AO in PBS), and visu-
alized under a uorescence microscope (Carl Zeiss).This journal is © The Royal Society of Chemistry 20162.11 DHR and CFSE staining
At rst cells were stained with DHR or CFSE analogously as
described in the literature.53,54 B16F10 cells were seeded in the
6 well plate at density of 1  105 cells per well. Aer 24 h cells
were incubated with IC50, 2  IC50 or MC50, 2  MC50 doses of
CP and SBA-15|CP. Flow cytometry was performed for DHR and
CFSE assay aer for 48 and 72 h of treatment, respectively.2.12 Senescence (SA-b-gal) assay
B16F10 cells were seeded overnight on 4 chamber slides (10 000
cells per chamber) in 500 mL of complete medium. The next day,
cells were treated with IC50 and MC50 doses of CP and
SBA-15|CP, respectively for 48 h. The medium was removed
and cells were washed in PBS, xed and stained with a b-
galactosidase reagent. Chamber slides were incubated over
night at 37 C without CO2 and then observed in bright and
uorescence eld under a uorescence microscope (Carl Zeiss).3 Results and discussion
3.1 Preparation of mesoporous silica materials
The selection of CP was rstly due to the known biological
potential.55 Moreover, inspired with previous results on SBA-15
derivative loaded with Ph3Sn(CH2)6OH,44 it is of interest to
investigate if the antitumor activity of CP can be improved by
using SBA-15 carrier particles. Also, K2[PtCl4] (TC) as
antitumor inactive platinum(II) complex graed into SBA-15
(/SBA-15|TC), was parallel used for desorption and in vitro
studies. Preparation of SBA-15 was performed according to the
literature procedures.56 SBA-15|TC and SBA-15|CP were
prepared by loading of TC and CP, respectively, into SBA-15. The
SBA-15|TC and SBA-15|CP nanomaterials, as well as SBA-15,
have been extensively characterized. For detection and quanti-
cation of platinum in SBA-15|TC and SBA-15|CP particles EDX
analysis was performed. The evaluation showed that loading of
the platinum(II) complexes TC and CP in SBA-15 occurred
successfully (SBA-15|TC: 2.0 wt% Pt; SBA-15|CP: 12.1 wt% Pt).
SEM and TEM analyses were used to investigate whether
a change or damage of starting SBA-15 had occurred upon
loading of platinum(II) complexes (Fig. 1). A uniform
morphology with hexagonal distribution of rod-shaped MSNs
(mesoporous silica nanoparticles, herein: SBA-15, SBA-15|TC
and SBA-15|CP) was observed by SEM and TEM analyses. The
dimensions of nanomaterials before and aer the loading are
with narrow size distribution (approximately 200–400  600–
800 nm). The physical parameters of nitrogen adsorption–
desorption isotherms, BET surface area, average pore diameter,
average pore volume, and wall thickness for the three MSNs
were measured.
The mesoporous nature of nanomaterials was conrmed by
nitrogen adsorption–desorption analysis, thus type IV
isotherms57 were observed for all materials (Fig. 2A). The
hysteresis loop generally appeared between the adsorption and
desorption branches, which indicates the capillary condensa-
tion of porous structure. In all cases, the capillary condensation
of nitrogen started at p/p0¼ 0 and extended up to 1, proving theRSC Adv., 2016, 6, 111031–111040 | 111033
Fig. 2 (A) N2 adsorption–desorption isotherms; (B) SAXS patterns and (C)
29Si MAS NMR spectra of MSNs.
Fig. 1 SEM (upper) and TEM images (lower) of MSNs: SBA-15, SBA-15|TC and SBA-15|CP.
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View Article Onlinewide pore distribution in the synthesized MSNs. The pore
diameter as well as surface area of MSNs decreased upon
loading with platinum(II) complexes (Table 1). This can clearly
be seen by the decrease of absolute absorbed volume of
nitrogen in MSNs (Fig. 2A).
Uniform pore diameter of 4.88 (SBA-15), 4.62 (SBA-15|TC)
and 4.41 nm (SBA-15|CP) was determined. A high BET surface of
810, 522 and 561 m2 g1 (SBET) for SBA-15, SBA-15|TC and SBA-
15|CP, respectively, were noticed. In combination with small-
angle X-ray scattering experiments (SAXS) wall thickness was
determined: 4.64 nm SBA-15|TC, 4.51 nm SBA-15|CP (increased
in comparison to SBA-15: 4.39 nm). In addition to wall thick-
nesses lattice parameters and crystallite sizes are also dened.
For all materials similar values for the lattice parameter could
be detected. This was expected since this parameter species
the repetition rate of the hexagonal pores of the MSNs. The
crystallite size (calculated by the Debye–Scherrer equation)
determined for all nanomaterials is almost identical. From the
slight variations of this parameter can be concluded that the
particles are structurally unchanged. Consequently, it can be
conrmed that TC or CP loading of SBA-15 did not have any
inuence on the structure.
The X-ray reections from the unit cell can be assigned to the
a-quartz, trigonal, P32. A well-resolved pattern at low 2q values
with a very sharp (100) diﬀraction peak was observed for all111034 | RSC Adv., 2016, 6, 111031–111040three MSNs (Table 1 and Fig. 2B). X-ray diﬀraction pattern
(XRD) of the MSNs displayed reections typical for hexagonally
ordered mesoporous materials.47 In the 29Si MAS NMR spectra
of all materials typical resonances at 91.5, 101.4 and
108.9 ppm assigned to [Si(OSi)2(OH)2] (Q2), [Si(OSi)3(OH)] (Q3)
and [Si(OSi)4] (Q4),43 respectively, were observed (Fig. 2C).
From the IR spectra of MSNs asymmetrical stretching
vibrations of Si–O–Si are found at around 1060 cm1.58 These
absorptions correspond to the silicon framework. Symmetrical
stretching vibrations of Si–O–Si (ring structures) are found at
around 806 cm1, while corresponding bending vibrations are
located at around 443 cm1. Additionally, in the IR spectra of
SBA-15|TC and SBA-15|CP bands at 325 cm1 originate from
Pt–Cl stretching vibrations.3.2 Release of CP from the SBA-15|CP particles
To obtain a rst insight into the desorption behavior of the
platinum(II) compounds, TC and CP, from SBA-15|TC and
SBA-15|CP drug release studies were conducted. To simplify
system these investigations were carried out in puried water.
The SBA-15|TC and SBA-15|CP materials were soaked in
puried water and aer 0.08, 0.5, 1, 3, 6, 12, 24 and 48 h assayed
for their metal contents by means of EDX and ICP-MS. The
results of these studies are summarized in Fig. 3.This journal is © The Royal Society of Chemistry 2016
Table 1 Selected physical parameters of the MSNs used
MSNs
SBET
[m2 g1]
Wall thickness
[nm]
Pore diameter
[nm]
Pore volume
[cm3 g1]
Lattice parameter a
[nm]
XRD
2q
[] hkl
Crystal size
[nm]
SBA-15 810 4.39 4.88 0.83 9.3 0.9512 100 75.50
1.6647 111
1.8956 200
SBA-15|TC 522 4.64 4.62 0.55 9.3 0.9617 100 77.54
1.6437 111
1.9061 200
SBA-15|CP 561 4.51 4.41 0.59 8.9 1.0142 100 75.26
1.6963 111
1.9585 200
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View Article OnlineThe evaluation of TC and CP desorption from SBA-15|TC
and SBA-15|CP, respectively, shows that the nanomaterials
behave quite similar (Fig. 3, le). Aer short time chlorine,
potassium or platinum could not be detected by EDX in loaded
SBA-15. The contents of these elements could be determined
only at below 0.1 at% from 0.5 h desorption time (absolute
error of 0.1 at%). The ndings are in agreement with litera-
ture observations.28 Due to the high solubility of the plati-
num(II) complexes it was not possible to detect locally
increased concentrations on the surface of the carrier mate-
rial. In concordance to EDX, ICP-MS showed increased
concentration of platinum compounds in desorption medium
(Fig. 3, right).3.3 Cytotoxicity of SBA-15|CP particles
The in vitro anticancer activity of platinum(II) complexes (TC
and CP) as well as MSNs (SBA-15, SBA-15|TC and SBA-15|CP)
was assessed against four diﬀerent tumor cell lines: mouse
malignant melanoma B16F10, human adenocarcinoma HeLa,
colon HT-29 and prostate PC3. CV andMTT assays were used for
investigations upon 48 h of treatment with investigated
compounds and MSNs (Fig. 4). Furthermore, cytotoxicity of
SBA-15 against same tumor cell lines was determined. The IC50
and MC50 values are reported in Tables 2 and 3.Fig. 3 Release study of platinum(II) complexes from the SBA-15|TC and
found Pt content in solution (right, ICP-MS analysis). For comparison, the
0 h).
This journal is © The Royal Society of Chemistry 2016The CV and MTT results are in good agreement with except
of CP and SBA-15|CP against HT-29 cell line. Thus, in that case
respiration of the HT-29 cells are aﬀected with both CP and
SBA-15|CP. However, this eﬀect is slightly more enhanced with
SBA-15|CP. As shown previously SBA-15 was found to be inactive
(>100 mg mL1) against tumor cell lines.44
Furthermore, TC was ineﬀective against all investigated
tumor cell lines (>100 mM). Expectedly, SBA-15|TC did not show
any activity too (>100 mg mL1). The most eﬀective agents were
found to be CP and SBA-15|CP against B16F10 cell line. The
activity of SBA-15|CP is ca. 300 times higher than that of the
most active SBA-15 loaded with titanocene compound [Ti
{Me2Si(h
5-C5Me4)(h
5-C5H4)}Cl2] (MC50 ¼ 309  42 mg mL1),43
and its activity is twice as high as functionalized SBA-15 deriv-
ative with tetraorganotin(IV) compound (2 mg mL1;
Ph3Sn(CH2)6OH).44
Slightly higher or similar activity of SBA-15|CP in compar-
ison to CP against HT-29 as well as HeLa and PC3 cells lines,
respectively, was found. Most importantly, taking into consid-
eration a low platinum content in SBA-15|CP (12.1 wt%) the
eﬀectiveness of the lower concentration of CP in mentioned
material is 3.5 times higher against B16F10 than the activity of
CP alone. In respect to this, when applied in vivo SBA-15|CP
presumably will cause fewer side eﬀects than CP due to its lower
concentration.SBA-15|CP, remaining Pt content of carrier material (left, EDX analysis),
metal contents of unsoaked dry nanomaterials are shown as well (left:
RSC Adv., 2016, 6, 111031–111040 | 111035
Fig. 4 Survival of tumor cells S (in %) treated with CP (cisplatin) and SBA-15|CP (48 h).
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View Article Online3.4 SBA-15|CP enhances ROS formation, abrogates
proliferation, induces morphological changes and provokes
autophagy in B16F10 cells
In order to dene mechanism of action B16F10 cells were
treated with free CP as well as loaded into SBA-15 and cell cycle
analysis was performed (Fig. 5A). Both, CP and SBA-15|CP
slightly elevated cell population in sub-G1 phase aer 24 h of
treatment. There was almost no alteration on B16F10 cell cycle
distribution in treatment with single or double IC50 and MC50
doses. On the other hand, cells treated for 48 h behaved
diﬀerently depending on the dose and applied agent.
With higher concentration CP and SBA-15|CP induced M/G2
phase arrest. However, to some extent increased number of the
cells was found in sub-G1 population aer 48 than 24 h of
treatment. This was connected with induction of apoptotic cell
death.
To verify the apoptotic process annexin V/PI staining was
performed (Fig. 5B). Elevated both early and late apoptotic
B16F10 cells could be detected for cells treated with respectiveTable 2 IC50 [mM] and MC50 [mg mL
1] values of TC (K2[PtCl4]), CP
(cisplatin), SBA-15, SBA-15|TC and SBA-15|CP determined with CV
assay (48 h)
Compound/
material B16F10 HeLa HT-29 PC3
IC50 [mM]
TC >100
CP 1.49  0.14 2.29  0.17 5.03  0.52 10.66  0.49
SBA-15|CPa 0.43  0.03 3.03  0.55 3.97  0.11 9.47  1.43
MC50 [mg mL
1]
SBA-15 >100
SBA-15|TC >100
SBA-15|CP 1.06  0.08 7.50  1.36 9.81  0.26 23.42  3.55
a Recalculated from platinum content (EDX).
111036 | RSC Adv., 2016, 6, 111031–111040IC50/MC50 doses. Furthermore, with twice higher concentra-
tions boosted early (SBA-15|CP) and late apoptotic (CP) cells
were identied. In order to evaluate the biological eﬀect of CP-
and SBA-15|CP-induced generation of ROS in cancer cells, DHR
pretreated B16F10 cells following exposure to CP and SBA-15|CP
were investigated (Fig. 5C).
It was found that free CP as well as loaded into SBA-15 (in
IC50/MC50 doses) are elevating production of ROS. This eﬀect
was more pronounced by SBA-15|CP in higher than in lower
concentration. CFSE-labeled B16F10 cells were cultured with CP
and SBA-15|CP for 72 h. Cell proliferation was signicantly
inhibited by both, CP and SBA-15|CP. Remarkably, B16F10
proliferation was inhibited by more than 60% before rst divi-
sion by CP and SBA-15|CP.
However, morphological changes have been noticed in the
cells treated with SBA-15|CP. Because of that AO staining was
performed and cells were visualized under uorescent micro-
scope (Fig. 6). The cells treated with CP exhibit typical features
of apoptosis, in spite of this, rarely some larger cells could be
identied. On the other side beside small number of apoptoticTable 3 IC50 [mM] and MC50 [mg mL
1] values of TC, CP, SBA-15, SBA-
15|TC and SBA-15|CP determined with MTT assay (48 h)
Compound/
material B16F10 HeLa HT-29 PC3
IC50 [mM]
TC >100
CP 1.29  0.16 1.32  0.09 0.92  0.33 9.26  3.03
SBA-15|CPa 0.72  0.20 2.54  0.15 0.62  0.15 6.32  0.84
MC50 [mg mL
1]
SBA-15 >100
SBA-15|TC >100
SBA-15|CP 1.79  0.49 6.28  0.36 1.53  0.40 15.63  2.08
a Recalculated from platinum content (EDX).
This journal is © The Royal Society of Chemistry 2016
Fig. 5 Eﬀect of CP and SBA-15|CP on B16F10 cells: (A) cell cycle analysis (24 and 48 h), (B) induction of apoptosis (48 h), (C) formation of ROS (48
h) and (D) proliferation potential (72 h; O – undivided cells, I – ﬁrst and II – second cell generations).
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View Article Onlinecells, B16F10 cells treated with SBA-15|CP exhibited diﬀerent
morphology than untreated cells. Thus, larger cells with at-
tened morphology were observed. Similar morphological
changes were observed on the same tumor cell line when
treated with CP polymeric nanocarrier,59 but was not further
evaluated. Changed morphology of the cells can be correlated to
proliferation potential detriment of the cells treated with
SBA-15|CP and might point to changes in cellular phenotype of
B16F10 cells induced with such MSNs.
Moreover, rare structures suspected as autophagosomes
were detected. In order to investigate if CP alone or SBA-15|CP is
inducing autophagy in B16F10 cells ow cytometry analysis was
performed (Fig. 6). CP caused slightly elevated autophagy upon
treatment with IC50 and 2  IC50 doses. SBA-15|CP insigni-
cantly increased formation of autophagic vesicles in MC50 dose.
Contrary, in higher concentration (2  MC50) SBA-15|CP dras-
tically enhanced number of autophagic cells was detected.Fig. 6 Morphological changes (A) and autophagy induction (A and B)
in B16F10 cells treated with CP and SBA-15|CP, respectively.3.5 SBA-15|CP induces senescence in B16F10 cells
Taking all ndings together pointing phenotype changes in
B16F10 cells, which might be indicative of senescence. Sen-
escent cells accumulate a senescence-associated b-galactosidase
(b-gal) activity that distinguishes them from most quiescent
cells.60,61 The senescence induction could be identied investi-
gating b-gal activity, which is undetectable in quiescent,
immortal or tumor cells.62 In order to conrm this assumption,
B16F10 cells were treated with CP or SBA-15|CP and analyzed
using senescence-associated b-gal assay (Fig. 7). It became
obvious that some CP treated B16F10 cells were enlarged with
low b-gal activity, seen as rare small blue staining of the cells.
Such behavior can be correlated with slight autophagy elevation
caused by CP. On the contrary, B16F10 cells treated with SBA-
15|CP showed clear proofs that such cells undergo senescence.
Also here a higher eﬀect is detected for SBA-15|CP, even CPThis journal is © The Royal Society of Chemistry 2016quantity in SBA-15 is in lower amount abundant. Senescent cells
regularly down-regulate proliferation and extracellular matrix
production.63 It is well known that senescent cells oen develop
a large, attened morphology.64 In some cells ROS production is
associated with induction of senescence.65
Autophagy and senescence are closely related but not
necessarily interdependent responses, nevertheless autophagy
can facilitate and accelerate the development of the senescent
phenotype.66,67 On the other side, senescence may occur without
presence of autophagy.68 Both could serve to collaterally protect
the cell from the toxicity of external stress such asRSC Adv., 2016, 6, 111031–111040 | 111037
Fig. 7 Cytochemical staining of senescence-associated b-gal activity in B16F10 cells treated with CP and SBA-15|CP (after 48 h).
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View Article Onlinechemotherapy.69 Stress-induced senescence has been associ-
ated with drugs acting on DNA as shown for 5-uorouracil.70,71 It
is well known that CP also interacts with DNA.12,72 Since
SBA-15|CP trigger formation of ROS in B16F10 cells the mode of
action of this specic MSNs may be connected to stress-induced
senescence.
Moreover, in senescent cells autophagy serves as adaptation
mechanism to stress.65 This can be correlated to the results
reported herein, because SBA-15|CP enhances autophagy in
B16F10 cells. Signicantly, such mode of drug action presents
a harmless approach in tumor treatment, since senescent
tumor cells can be cleared by immune cells and this may result
in eﬃcient tumor regression.73
4 Conclusions
SBA-15|CP possesses great anticancer potential under in vitro
conditions. All four cell lines B16F10, HeLa, HT-29 and PC3
were much more or similarly sensitive to SBA-15|CP as free CP,
even if CP is present in lower concentration. However, there was
minimal induction of apoptosis caused by SBA-15|CP.
Contrarily, a clear evidence for morphological changes, auto-
phagy induction, prevention of proliferation and ROS forma-
tion, whereas the survived cells showed to be in a state of
senescence. Even so, the eﬀective controlling of stress is deci-
sive for tumor suppression in which autophagy plays a crucial
role. Cells under stress trigger autophagy, which can accelerate
senescence or protect cell to allow recovery of normal cell
function as tumor suppression mechanisms. Taken together,
data reported herein suggest that SBA-15 potentiates and
changes targeting activity of CP. This approach presents a safer
mode in tumor treatment compared to induced apoptosis
alone. The uniqueness of SBA-15 nanostructured materials
derives from their loading suitability with antitumor active
compounds. Furthermore, this approach showed potentiation
of the mechanism of action of the compounds by SBA-15.
Therefore, research in this eld is intensively proceeding in
last few years.74
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